Another promising PI3Kδ isoform-specific PI3K inhibitor is IPI-145 (Infinity Pharmaceuticals) which has also demonstrated impressive results in patients with relapsed haematological cancers, including CLL and lymphoma [30]. The gene discussed is PIK3CG; the disease is B-cell chronic lymphocytic leukemia.